Difference in immune infiltration in MSI and MSS BRAF mutant colorectal cancer.
Elena Bolzacchini, Daniela Furlan(University of Insubria), Salvatore Artale(Ospedale San Carlo), Roberta Cerutti, Claudio Verusio(Medica (Italy)), Nunzio Digiacomo(University of Insubria), Nora Sahnane(University of Insubria), Marco Bregni(Ospedale San Giuseppe), Filippo Crivelli, Carlo Capella(University of Insubria), Graziella Pinotti(Medica (Italy)), Fausto Sessa(University of Insubria)
Cited by 1
Related Papers
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
|New England Journal of Medicine|2009|1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684